The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Regenacy Pharmaceuticals
Stock and Other Ownership Interests - Regenacy Pharmaceuticals
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced ccRCC.
 
Miso Kim
Honoraria - Astellas Pharma; Merck; Novartis; Yuhan
Consulting or Advisory Role - Astellas Pharma; Bayer; Bayer; Boryung; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche; Yuhan
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Stephen K. Williamson
Stock and Other Ownership Interests - Horizon Therapeutics; Iovance Biotherapeutics; Merus
Research Funding - Acceleron Pharma (Inst); Aleon Pharma (Inst); Astellas Pharma (Inst); Bayer Health (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Merck Serono (Inst); Nektar (Inst); Novartis (Inst); Pharmacyclics (Inst); Regeneron (Inst); Rogosin Institute (Inst); Sanofi (Inst); Seagen (Inst); Sotio (Inst)
 
Byoung Chul Cho
Leadership - Interpark Bio; J Ints Bio
Stock and Other Ownership Interests - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; J INTS BIO; Kanaph Therapeutics; Theravance
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; CJ bioscience; CureLogen; Cyrus therapeutics; GI Cell; Guardant Health; Hanmi; Imnewrun; inno.N; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Onegene Biotechnology; Ono Pharmaceutical; Oscotec; Pfizer; RandBio; Roche; Takeda; Yuhan
Research Funding - Abbvie; Abion; AstraZeneca; Bayer; Blueprint medicines; Boehringer Ingelheim; Bridgebio; CHA Bundang Medical Center; Champions Oncology; CJ bioscience; CJ Blossom Park; Cyrus Therapeutics; Dizal Pharma; Dong-A ST; Genexine; GI Cell; GI Innovation; Hanmi; Illumina; ImmuneOncia; Interpark Bio; J Ints Bio; Janssen; Kanaph therapeutics; LG Chem; Lilly; Mogam Biotechnology Research Institue; MSD; Novartis; Nuvalent, Inc.; Oncternal Therapeutics; Ono Pharmaceutical; Oscotec; Regeneron; Therapex; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology; Crown Bioscience; Imagen
Other Relationship - DAAN Biotherapeutics
 
Afshin Dowlati
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN,; Jazz Pharmaceuticals; Prelude Corporation; Puma Biotechnology
 
Nehal J. Lakhani
Consulting or Advisory Role - Ikena Oncology; SK Life Sciences
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Jyoti Malhotra
Consulting or Advisory Role - AstraZeneca; BeiGene; BioAtla; Catalyst Pharmaceuticals; Mirati Therapeutics; OncoCyte; Regeneron; Sanofi; Takeda
Research Funding - BeyondSpring Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Daiichi Sankyo (Inst)
 
John M. Kaczmar
Stock and Other Ownership Interests - HCA Healthcare (I)
Honoraria - The Scienomics Group; Triangle Insights Group
Consulting or Advisory Role - Bicara Therapeutics; Coherus Biosciences; Rakuten Medical
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Howard Safran
No Relationships to Disclose
 
Raid Aljumaily
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Regeneron
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Jayakumar Mani
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Fang Fang
Employment - Regenacy Pharmaceuticals
Stock and Other Ownership Interests - Regenacy Pharmaceuticals
 
Shuquan Chen
Employment - Regenacy Pharmaceuticals
Stock and Other Ownership Interests - Regenacy Pharmaceuticals
 
Mark Salvati
Employment - Amgen; Regeneron
Stock and Other Ownership Interests - Amgen; Regeneron
 
Israel Lowy
Employment - Regenacy Pharmaceuticals
Stock and Other Ownership Interests - Regenacy Pharmaceuticals
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Karl Lewis
No Relationships to Disclose